Healthcare -
Biotechnology - NASDAQ - US
$ 36.72
1.18 %
$ 5.83 B
Market Cap
146.88
P/E
1. INTRINSIC VALUE
Balance Sheet
TG Therapeutics, Inc.
| Current Assets | 566 M |
| Cash & Short-Term Investments | 311 M |
| Receivables | 129 M |
| Other Current Assets | 126 M |
| Non-Current Assets | 11.3 M |
| Long-Term Investments | 2.11 M |
| PP&E | 7.15 M |
| Other Non-Current Assets | 2.07 M |
| Current Liabilities | 90.7 M |
| Accounts Payable | 58.3 M |
| Short-Term Debt | 1.82 M |
| Other Current Liabilities | 30.6 M |
| Non-Current Liabilities | 265 M |
| Long-Term Debt | 253 M |
| Other Non-Current Liabilities | 12.1 M |
EFFICIENCY
Earnings Waterfall
TG Therapeutics, Inc.
| Revenue | 329 M |
| Cost Of Revenue | 38.5 M |
| Gross Profit | 291 M |
| Operating Expenses | 249 M |
| Operating Income | 41.9 M |
| Other Expenses | 18.5 M |
| Net Income | 23.4 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
TG Therapeutics, Inc.
| Net Income | 23.4 M |
| Depreciation & Amortization | 280 K |
| Capital Expenditures | -45 K |
| Stock-Based Compensation | 42.5 M |
| Change in Working Capital | -109 M |
| Others | 15.4 M |
| Free Cash Flow | -40.6 M |
Wall Street Analysts Price Targets
TG Therapeutics, Inc.
Wall Street analysts predict an average 1-year price target for TGTX of $34.1 , with forecasts ranging from
a
low of
$16 to a high of $55 .
TGTX Lowest Price Target
Wall Street Target
16 USD
-56.43%
TGTX Average Price Target
Wall Street Target
34.1 USD
-7.02%
TGTX Highest Price Target
Wall Street Target
55 USD
49.78%
4. DIVIDEND
ANALYSIS
TGTX does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
TG Therapeutics, Inc.
Sold
0-3 MONTHS
369 K USD 1
3-6 MONTHS
286 K USD 1
6-9 MONTHS
1.74 M USD 4
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
TG Therapeutics: Another Possible Avenue Of MS Growth With Azer-Cel
TG Therapeutics, Inc.'s BRIUMVI saw Q1 2025 revenue surge 137% YoY to $119.7M, driven by strong U.S. growth. A subcutaneous version of TGTX's BRIUMVI is in phase 1 trials, with late-stage development planned for 2025, aiming to broaden patient reach and administration options. Azer-cel, an allogeneic off-the-shelf CD19 CAR-T, is in phase 1 for progressive MS, targeting a new MS market segment beyond relapsing MS.
seekingalpha.com
- 1 week ago
TG Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will participate in the Goldman Sachs 46th Annual Global Healthcare Conference, being held in Miami, FL on June 9-11, 2025.
globenewswire.com
- 1 month ago
TG Therapeutics: Estimates Could Soon Be Raised Again
TG Therapeutics remains on track, with Q1 revenue matching my model and potential for 110% growth in 2025 if price increases hold. Analyst estimates for 2025 revenue have risen sharply, and Q2 expectations now exceed both company guidance and my own projections. Recent price increases for Briumvi and pipeline catalysts like a subcutaneous version could drive further outperformance versus current expectations.
seekingalpha.com
- 1 month ago
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting
NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients with relapsing forms of multiple sclerosis (RMS), at the 2025 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting, being held May 28-31, 2025 in Phoenix, Arizona. Abstracts are now available online and can be accessed on the CMSC meeting website at www.mscare.org/2025. Details of the upcoming presentations are outlined below.
globenewswire.com
- 1 month ago
TG Therapeutics Falls Short On Earnings, But Briumvi Sales Steal the Show
TG Therapeutics Inc TGTX on Monday reported first-quarter earnings per share of 3 cents, a shift from a loss of 7 cents a year ago, but below the consensus of 17 cents.
benzinga.com
- 2 months ago
Why TG Therapeutics Stock Was Tumbling Today
A near-doubling of revenue and a flip into profitability on the bottom line apparently weren't good enough for TG Therapeutics (TGTX -12.32%) shareholders on Monday.
fool.com
- 2 months ago
TG Therapeutics: Share Price Slip On Q1 Earnings Unsurprising Given Challenges
TG Therapeutics' Q1 2025 earnings report showed strong revenue growth, with Briumvi net revenues rising to $119.7m, prompting an increase in full-year revenue guidance. Despite a >15% drop in stock value post-earnings, TGTX shares remain up significantly over 6 months, 1 year, and 5 years, reflecting strong market performance. Briumvi competes well against major MS therapies, boasting superior efficacy, less frequent dosing, and a promising subcutaneous version in development.
seekingalpha.com
- 2 months ago
TG Therapeutics, Inc. (TGTX) Q1 2025 Earnings Call Transcript
TG Therapeutics, Inc. (NASDAQ:TGTX ) Q1 2025 Earnings Conference Call May 5, 2025 8:30 AM ET Company Participants Jenna Bosco - Chief Communications Officer Michael Weiss - Chairman and Chief Executive Officer Adam Waldman - Chief Commercialization Officer Sean Power - Chief Financial Officer Conference Call Participants Tara Bancroft - TD Cowen Michael DiFiore - Evercore ISI Roger Song - Jefferies Mayank Mamtani - B. Riley Securities Prakhar Agrawal - Cantor Fitzgerald Operator Greetings, and welcome to TG Therapeutics First Quarter Conference Call and Webcast.
seekingalpha.com
- 2 months ago
TG Therapeutics (TGTX) Lags Q1 Earnings Estimates
TG Therapeutics (TGTX) came out with quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.18 per share. This compares to loss of $0.07 per share a year ago.
zacks.com
- 2 months ago
TG Therapeutics Reports First Quarter 2025 Financial Results and Raises BRIUMVI Full Year Revenue Guidance
First quarter 2025 BRIUMVI U.S. net revenue of $119.7 million Raises full year 2025 global net revenue target to approximately $575 million and raises full year BRIUMVI U.S. net revenue target to approximately $560 million Conference call to be held today, Monday, May 5, 2025, at 8:30 AM ET NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today announced its financial results for the first quarter of 2025, along with recent company developments and provided an update on 2025 revenue guidance. Michael S.
globenewswire.com
- 2 months ago
TG Therapeutics (TGTX) to Report Q1 Results: Wall Street Expects Earnings Growth
TG Therapeutics (TGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
zacks.com
- 2 months ago
TG Therapeutics to Host Conference Call on First Quarter 2025 Financial Results and Business Update
NEW YORK, April 30, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday, May 5, 2025, at 8:30 AM ET to discuss results for the first quarter of 2025 and provide a business outlook for the remainder of 2025. Michael S.
globenewswire.com
- 2 months ago
8. Profile
Summary
TG Therapeutics, Inc. TGTX
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 5.83 B
Dividend Yield
0.00%
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
Contact
2 Gansevoort Street, Morrisville, NY, 10014
https://www.tgtherapeutics.com
IPO
Date
May 3, 2010
Employees
352
Officers
Ms. Jenna Bosco
Senior Vice President of Corporate Communications
Mr. Adam Waldman
Chief Commercialization Officer
Mr. Michael S. Weiss Esq.
Chairman, Chief Executive Officer & President
Mr. Sean A. Power CPA
Chief Financial Officer, Corporate Secretary & Treasurer